VEGFA and neoplasm: Animal model studies have demonstrated that inhibition of VEGF and its related pathways normalizes tumor vasculature, reprogramming the tumor microenvironment from an immune-suppressive state to an immune-activated state.[42] Moreover, anti-angiogenic therapy can increase the formation of high endothelial venules, thereby enhancing tumor sensitivity to immunotherapy.[43] Therefore, the combination of anti-angiogenic drugs with ICIs may enhance the effectiveness of immunotherapy by improving the tumor microenvironment, making it a promising therapeutic strategy.